CoChat

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

Open access
Duffaud, Florence, Mir, Olivier, Boudou-Rouquette, Pascaline, Piperno-Neumann, Sophie, Penel, Nicolas, Bompas, Emanuelle, Delcambre, Corinne, Kalbacher, Elsa, Italiano, Antoine, Collard, Olivier, Chevreau, Christine, Saada, Esma, Isambert, Nicolas, Delaye, Jessy, Schiffler, Camille, Bouvier, Corinne, Vidal, Vincent, Chabaud, Sylvie, Blay, Jean-Yves · 2019 · The Lancet Oncology

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Background Regorafenib has proven activity in patients with pretreated gastrointestinal stromal tumours and colorectal and hepatocellular carcinoma. We designed REGOBONE to assess the efficacy and safety of regorafenib for patients with progressive metastatic osteosarcoma and other bone sarcomas. This trial comprised four parallel independent cohorts: osteosarcoma, Ewing sarcoma, chondrosarcoma, and chordoma. In this Article, we report the results of the osteosarcoma cohort.Methods In this non-comparative, double-blind, placebo-controlled, phase 2 trial, patients aged 10 years or older with histologically confirmed osteosarcoma whose disease had progressed after treatment with one to two previous lines of chemotherapy for metastatic disease and an Eastern Cooperative Oncology Group performance status of 0 or 1 were enrolled. Patients were randomly assigned (2:1) to receive either oral regorafenib (160 mg/day, for 21 of 28 days) or matching placebo. Patients in both groups also received best supportive care. Randomisation was done using a web-based system and was stratified (permuted block) by age at inclusion (<18 vs ≥18 years old). Investigators and patients were masked to treatment allocation. Patients in the placebo group, after centrally confirmed progressive disease, could cross over to receive regorafenib. The primary endpoint was the proportion of patients without disease progression at 8 weeks. Analyses were done by modified intention to treat (ie, patients without any major entry criteria violation who initiated masked study drug treatment were included). All participants who received at least one dose of study drug were included in the safety analyses. This study is registered with ClinicalTrials.gov, number NCT02389244, and the results presented here are the final analysis of the osteosarcoma cohort (others cohorts are ongoing).Findings Between Oct 10, 2014, and April 4, 2017, 43 adult patients were enrolled from 13 French comprehensive cancer centres. All patients received at least one dose of assigned treatment and were evaluable for safety; five patients were excluded for major protocol violations (two in the placebo group and three in the regorafenib group), leaving 38 patients who were evaluable for efficacy (12 in the placebo group and 26 in the regorafenib group). 17 of 26 patients (65%; one-sided 95% CI 47%) in the regorafenib group were non-progressive at 8 weeks compared with no patients in the placebo group. Ten patients in the placebo group crossed over to receive open-label regorafenib after centrally confirmed disease progression. 13 treatment-related serious adverse events occurred in seven (24%) of 29 patients in the regorafenib group versus none of 14 patients in the placebo group. The most common grade 3 or worse treatment-related adverse events during the double-blind period of treatment included hypertension (in seven [24%] of 29 patients in the regorafenib group vs none in the placebo group), hand-foot skin reaction (three [10%] vs none), fatigue (three [10%] vs one [3%]), hypophosphataemia (three [10%] vs none), and chest pain (three [10%] vs none). No treatment-related deaths occurred.Interpretation Regorafenib demonstrated clinically meaningful antitumour activity in adult patients with recurrent, progressive, metastatic osteosarcoma after failure of conventional chemotherapy, with a positive effect on delaying disease progression. Regorafenib should be further evaluated in the setting of advanced disease as well as potentially earlier in the disease course for patients at high risk of relapse. Regorafenib might have an important therapeutic role as an agent complementary to standard cytotoxic chemotherapy in the therapeutic armamentarium against osteosarcoma.Funding Bayer HealthCare.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(18)30742-3

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Cited by

See all 331

Metadata

Authors
Duffaud, F., Mir, O., Boudou-Rouquette, P., Piperno-Neumann, S., Penel, N., Bompas, E., Delcambre, C., Kalbacher, E., Italiano, A., Collard, O., Chevreau, C., Saada, E., Isambert, N., Delaye, J., Schiffler, C., Bouvier, C., Vidal, V., Chabaud, S., & Blay, J.-Y.
Affiliations
  • Aix-Marseille Université (FR)
  • Institut Gustave Roussy (FR)
  • Institut Curie (FR)
  • Centre Hospitalier Universitaire de Lille (FR)
  • Centre François Baclesse (FR)
  • Centre Hospitalier Universitaire de Besançon (FR)
  • Institute Cancer De La Loire Lucien Neuwirth (FR)
  • Institut universitaire du cancer de Toulouse Oncopole (FR)
  • UniCancer Group (FR)
  • Centre Léon Bérard (FR)
Corresponding author
Duffaud, Florence
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2019-01
Volume
20
Issue
1
Pages
120-133
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2901259053
Cited by
331
References
35
Citations by year
2026: 28 · 2025: 33 · 2024: 36 · 2023: 55 · 2022: 41 · 2021: 61 · 2020: 52 · 2019: 24
FWCI
25.97
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Oncology (acceptedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
  • Institut National Du Cancer
  • Unicancer
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
  • Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords
metastatic osteosarcoma, bone sarcoma, Ewing sarcoma, chondrosarcoma, chordoma, multikinase inhibitor, progression-free survival, overall survival, safety, adult patients, best supportive care
MeSH terms
Progression-Free Survival, Adult, Antineoplastic Agents, Bone Neoplasms, Double-Blind Method, Female, Humans, Male, Middle Aged, Phenylurea Compounds, Pyridines, Osteosarcoma, Treatment Outcome, Angiogenesis Inhibitors, Protein Kinase Inhibitors, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. https://app.cochat.ai/papers/10.1016/s1470-2045(18)30742-3
The paper
Duffaud, F., Mir, O., Boudou-Rouquette, P., Piperno-Neumann, S., Penel, N., Bompas, E., Delcambre, C., Kalbacher, E., Italiano, A., Collard, O., Chevreau, C., Saada, E., Isambert, N., Delaye, J., Schiffler, C., Bouvier, C., Vidal, V., Chabaud, S., & Blay, J.-Y. (2019). Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(18)30742-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.